GSWM
ABCL icon

Golden State Wealth Management’s AbCellera Biologics ABCL Stock Holding History

Golden State Wealth Management’s Portfolio ABCL Stock Details ABCL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$236K Buy
+30,000
New +$147K 0.02% 396

Other funds holding ABCL

CMF
Counterpoint Mutual Funds San Diego, California $1.01B AUM 37.65% 1-Year Est. Return
DRP
Decker Retirement Planning Levi, Utah $294M AUM 97.44% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
HOWA
Heritage Oak Wealth Advisors Santa Rosa Beach, Florida $340M AUM 29.73% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
AWM
Apollon Wealth Management Mount Pleasant, South Carolina $8.23B AUM 30.88% 1-Year Est. Return
FA
Fedenia Advisers Madison, Wisconsin $421M AUM 96.46% 1-Year Est. Return
NA
Networth Advisors Canonsburg, Pennsylvania $172M AUM
BP
Ballentine Partners Waltham, Massachusetts $8.18B AUM 27.59% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Golden State Wealth Management's ABCL Position: Q2 2026 in Review

Golden State Wealth Management opened a new position in AbCellera Biologics (ABCL) in Q2 2026: 30,000 shares worth $236K. The stake represents 0.02% of the portfolio and ranks #396 among its holdings.

18 funds tracked by Wall St. Rank hold ABCL as of Q2 2026.

  • Golden State Wealth Management held 30,000 shares of AbCellera Biologics worth $236K as of Q2 2026.
  • AbCellera Biologics was a new Golden State Wealth Management position in Q2 2026.
  • AbCellera Biologics made up 0.02% of Golden State Wealth Management's portfolio in Q2 2026, its #396 holding.
  • 18 funds tracked by Wall St. Rank held AbCellera Biologics as of Q2 2026.

Based on Golden State Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.